Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10) — specifically the sequence Met-Glu-His-Phe-Pro-Gly-Pro — developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was originally designed as a neuroprotective agent for stroke recovery and has been approved in Russia and several former Soviet states as a prescription medication for cerebrovascular disease, cognitive disorders, and optic nerve atrophy.

What distinguishes Semax from other nootropic peptides is the breadth and strength of its neurotrophic activity. Semax produces robust upregulation of brain-derived neurotrophic factor (BDNF), the primary neurotrophin responsible for synaptic plasticity, memory consolidation, and long-term potentiation — the cellular mechanism underlying learning. It also modulates dopaminergic and serotonergic neurotransmission, providing the attentional and motivational substrate that converts enhanced neuroplasticity into actual cognitive performance.

This protocol focuses on cognitive enhancement in otherwise healthy individuals seeking improved focus, memory, processing speed, and creative problem-solving capacity.

Dose selection

Semax dosing is simpler than many peptide protocols because the therapeutic window is relatively wide and the compound is well-tolerated across the effective dose range.

Starting dose: 200 mcg per administration, 1-2 times daily. This is the minimum effective dose for cognitive enhancement in most individuals. It provides measurable BDNF upregulation and noticeable improvements in focus and mental clarity without risk of overstimulation.

Standard dose: 300-400 mcg per administration, 2 times daily. This is the dose range used in most Russian clinical protocols and represents the best balance of efficacy and tolerability. Total daily dose of 600-800 mcg.

Upper dose: 600 mcg per administration, 2-3 times daily. This dose is used for more intensive cognitive demands or for individuals who have established tolerance at lower doses. Total daily dose up to 1,200-1,800 mcg. Higher doses increase BDNF upregulation but also increase the likelihood of mild side effects (headache, irritability).

NA-Semax-Amidate: This modified form (N-acetyl Semax with C-terminal amidation) resists enzymatic degradation more effectively than standard Semax, resulting in longer duration of action and potentially greater potency per microgram. When using NA-Semax-Amidate, reduce the dose by 30-50% compared to standard Semax and assess response before escalating. A starting dose of 100-200 mcg of NA-Semax-Amidate is equivalent to approximately 200-400 mcg of standard Semax.

Dose escalation: Begin at 200 mcg once or twice daily for the first 3-5 days. If well tolerated and cognitive effects are insufficient, increase to 300-400 mcg twice daily. Assess at this dose for at least 5-7 days before considering further increases. Most users find their optimal dose within the first 10-14 days of a cycle.

Route and administration

Route: Intranasal only. Semax is administered as a nasal spray, exploiting the olfactory epithelium's direct connection to the central nervous system. This bypasses the blood-brain barrier and delivers the peptide directly to brain tissue — a significant advantage over systemic administration for a compound targeting CNS function.

Nasal spray preparation: Semax is typically supplied as a 1% solution (10 mg/mL), with each spray delivering approximately 100 mcg. Some formulations are available at 0.1% (1 mg/mL) for lower-dose applications. Verify the concentration of your specific product before calculating doses.

Administration technique:

Clear nasal passages before each dose. If congestion is present, use a saline rinse 10-15 minutes prior. Do not administer into a congested nostril.

Tilt the head slightly forward, chin toward chest. This directs the spray upward toward the olfactory epithelium at the roof of the nasal cavity. Tilting backward sends the spray toward the throat, reducing CNS delivery.

Insert the nozzle just inside the nostril, angling slightly toward the outer nasal wall (toward the ear on the same side). Spray while inhaling gently through the nose. Do not sniff forcefully.

Alternate nostrils between sprays. If the dose requires multiple sprays, wait 30-60 seconds between each to allow mucosal absorption.

Avoid blowing the nose for at least 15 minutes after administration.

Timing protocol:

Morning dose (primary): Within 30 minutes of waking. This aligns BDNF upregulation and dopaminergic stimulation with the morning period of peak cognitive demand. Take before breakfast — food in the stomach is irrelevant for intranasal administration, but the morning routine consistency aids compliance.
Midday dose: 4-6 hours after the morning dose, typically around noon. This maintains cognitive enhancement through the natural afternoon dip in alertness and executive function.
Evening dose (if applicable): Only for high-dose protocols. Must be taken by 4-5 PM. Semax has mild dopaminergic stimulant properties, and later administration can interfere with sleep onset in sensitive individuals.

Cycle structure

Semax is not used continuously. Cycling preserves receptor sensitivity, prevents neurotrophin pathway desensitization, and ensures that cognitive enhancements are maintained across cycles rather than requiring ever-increasing doses.

Standard cycle: 14-21 days on, 14-21 days off.

This mirrors the protocol used in Russian clinical practice. Two to three weeks of daily administration provides sufficient time for BDNF-mediated neuroplastic changes to take hold, while the off-period allows receptor systems to reset.

Extended cycle (for sustained demand periods): 28 days on, 14 days off. Appropriate for specific high-demand periods such as exam preparation, major project deadlines, or intensive learning phases. The 4-week active phase pushes the upper limit of cycling before diminishing returns set in. Do not exceed 28 days without a break.

Cognitive maintenance cycling: For ongoing cognitive optimization over months, a repeating 3-weeks-on/2-weeks-off pattern provides 60% coverage while maintaining full receptor sensitivity. This is the approach most compatible with professional or academic demands that span entire semesters or quarters.

Transition between cycles: Cognitive benefits do not disappear immediately when Semax is discontinued. BDNF-driven neuroplastic changes — enhanced synaptic density, improved long-term potentiation efficiency — persist for days to weeks beyond the active dosing period. Most users report a gradual return to baseline over 7-14 days into the off-period, not an abrupt drop-off.

Signs that cycling is needed: Diminishing subjective benefit despite consistent dosing is the primary indicator that receptor desensitization is occurring. If focus enhancement that was initially robust begins to fade by week 3 or 4, the cycle should end and the off-period should begin regardless of the planned cycle length.

Combination options

Semax + Selank (the canonical nootropic stack): This is the most established peptide cognitive combination. Selank provides GABAergic anxiolytic tone and complementary BDNF modulation, while Semax provides dopaminergic activation and primary BDNF drive. Together they produce calm, focused cognitive enhancement — the "relaxed intensity" that neither compound achieves as effectively alone.

Administration protocol: Selank first (250-500 mcg intranasal), wait 15-30 minutes, then Semax (200-600 mcg intranasal). Administer Selank first to establish the anxiolytic foundation before adding Semax's activating properties. This sequence prevents the "wired but anxious" state that some individuals experience with Semax alone.

Semax + Cerebrolysin: Cerebrolysin is a porcine brain-derived peptide mixture containing multiple neurotrophic factors. Combining it with Semax provides multimodal neurotrophic support — Semax through defined BDNF and NGF pathways, Cerebrolysin through a broader but less precisely characterized neurotrophic cocktail. This combination is used in clinical neurorehabilitation contexts but is also employed by biohackers targeting maximum neuroplastic enhancement. Cerebrolysin is administered intramuscularly, typically 5-10 mL daily for 10-20 days, overlapping with the Semax intranasal cycle.

Semax + Pinealon: Pinealon is a tripeptide (Glu-Asp-Arg) that targets the pineal gland and has been studied for neuroprotective and cognitive effects. It provides a complementary mechanism focused on neuroprotection and circadian rhythm support rather than direct cognitive stimulation. Pinealon is typically administered intranasally or sublingually, and its mild profile makes it a low-risk addition to a Semax protocol.

Semax + Foundational nootropic support:

Magnesium L-threonate (1,500-2,000 mg daily): Crosses the BBB effectively, supports NMDA receptor function, complements BDNF-driven plasticity
Lion's mane mushroom extract (500-1,000 mg daily): NGF upregulation through a pathway independent of Semax's BDNF mechanism
Omega-3 fatty acids (2-3 g EPA/DHA daily): Structural neuronal membrane support and anti-neuroinflammatory effects
Creatine monohydrate (3-5 g daily): ATP buffer for high-demand cognitive tasks

Combinations to avoid:

High-dose stimulants (above 400 mg caffeine, amphetamine-class drugs): Excessive dopaminergic stimulation combined with Semax's own dopaminergic activity can produce anxiety, irritability, and impaired rather than enhanced cognition
MAO inhibitors: Semax modulates monoamine metabolism; combining with MAOIs creates unpredictable monoamine accumulation
Multiple GABAergic compounds when stacking with Selank: If using Selank alongside Semax, do not add phenibut, gabapentin, or benzodiazepines

Monitoring

Cognitive enhancement is inherently subjective, which makes structured monitoring essential for distinguishing real effects from placebo response and optimizing the protocol across cycles.

Pre-cycle baseline (recommended):

Establish baseline cognitive performance using a consistent, repeatable metric. Options include dual n-back scores, reaction time tests (e.g., Cambridge Brain Sciences or similar online platforms), or a daily self-assessment log rating focus, memory, processing speed, and mental energy on a 1-10 scale
Sleep quality assessment (Pittsburgh Sleep Quality Index or subjective rating)
Mood and anxiety baseline (GAD-7 for anxiety, PHQ-9 for mood, or simple daily ratings)

During cycle:

Daily self-assessment log (same metrics as baseline, rated at the same time of day — midday is most informative)
Weekly objective cognitive test if using one (same test, same conditions)
Sleep quality monitoring — Semax should not impair sleep if timing is correct. If sleep deteriorates, the evening dose is too late or the total daily dose is too high
Note any headaches, irritability, or overstimulation symptoms with date, dose, and timing context

Post-cycle:

Repeat baseline cognitive assessment during the first week off to measure residual benefit
Repeat at the end of the off-period to measure return to baseline
Compare across cycles to identify the optimal dose and cycle length for your individual response

Blood work (optional but informative): Semax does not reliably alter standard blood markers. However, if using Semax as part of a comprehensive nootropic protocol, baseline and follow-up testing of thyroid function (Semax has minor effects on thyrotropin-releasing hormone metabolism), complete blood count, and comprehensive metabolic panel provide a general safety net.

Side effects and management

Semax has a well-established safety profile from decades of clinical use in Russia and neighboring countries. Side effects are generally mild and dose-dependent.

Nasal irritation: The most common complaint. Mild burning, stinging, or dryness in the nasal passages. This is a local effect of the solution, not a systemic reaction. Management: use saline nasal spray between Semax doses to maintain mucosal hydration. If irritation is severe, reduce the dose or frequency.

Headache: Reported by approximately 5-10% of users, most commonly during the first 3-5 days. Usually mild and transient. Related to increased cerebral blood flow and neurotrophic activation. Management: adequate hydration (2-3 L water daily), reduce dose temporarily if persistent. If headaches continue beyond the first week, reassess the dosing.

Overstimulation or irritability: More common at higher doses (above 600 mcg per administration) or when combined with caffeine or other stimulants. Presents as mental restlessness, difficulty relaxing, or shortened temper. Management: reduce the dose, eliminate or reduce caffeine, and ensure the last dose is before 3-4 PM.

Hair shedding: A rare but reported side effect, possibly related to Semax's effects on neurotrophins that also influence hair follicle cycling. Typically temporary and resolves during the off-period. If persistent across multiple cycles, discontinue Semax.

Sleep disruption: Not a direct pharmacological effect at appropriate doses and timing, but reported when the last dose is administered too late in the day. Management: ensure all Semax dosing is completed by 4-5 PM. If sleep disruption persists even with early dosing, reduce the total daily dose.

Emotional blunting (rare): A small number of users report reduced emotional reactivity at higher doses. This may relate to serotonergic modulation. Reducing the dose typically resolves this effect.

FAQ

How quickly does Semax work?

Acute cognitive effects are noticeable within 15-30 minutes of intranasal administration — improved focus, mental clarity, and reduced mental fatigue. These acute effects are mediated by rapid dopaminergic and serotonergic modulation. The deeper neuroplastic benefits — improved memory consolidation, enhanced learning capacity, increased cognitive resilience — develop over 7-14 days of consistent use as BDNF-driven synaptic remodeling accumulates. The first few days establish the immediate cognitive boost; the subsequent weeks build the structural neuroplastic foundation.

Is Semax a stimulant?

Semax has mild stimulant-like properties through its dopaminergic activity, but it is fundamentally different from classical stimulants like caffeine or amphetamines. It does not produce the sympathetic nervous system activation (elevated heart rate, vasoconstriction, sweating) associated with stimulants. It does not cause the "crash" that follows stimulant use. And its cognitive enhancement is not dependent on maintaining a certain blood level — the BDNF-mediated effects persist and accumulate independent of acute dosing. That said, individuals who are highly sensitive to any form of dopaminergic modulation should start at the lower end of the dose range and assess their response carefully.

Should I use Semax or Selank?

This depends on your primary cognitive challenge. If your cognitive limitation is attentional — difficulty sustaining focus, low mental energy, slow processing speed — Semax is the primary compound. If your cognitive limitation is stress-related — anxiety-driven cognitive impairment, difficulty thinking clearly under pressure, excessive mental reactivity to stressors — Selank is the primary compound. If both challenges are present (which is common), the combination protocol is appropriate. Most practitioners recommend trying each compound individually for one cycle before combining them, so you can identify each compound's specific contribution to your cognitive response.

Can Semax be used for conditions beyond cognitive enhancement?

Semax has clinical applications in Russia for stroke recovery, traumatic brain injury rehabilitation, optic nerve atrophy, and cognitive decline associated with cerebrovascular disease. These clinical applications are beyond the scope of this protocol, which focuses on cognitive optimization in healthy individuals. Individuals with neurological conditions should work with a qualified physician who can design a treatment-appropriate protocol.

What is the difference between Semax and NA-Semax-Amidate?

Standard Semax is the unmodified heptapeptide (ACTH 4-10 analog). NA-Semax-Amidate has two chemical modifications: an N-acetyl group and a C-terminal amide. These modifications protect the peptide from enzymatic degradation, extending its half-life and potentially increasing its potency. In practice, NA-Semax-Amidate lasts longer per dose and may be more potent microgram-for-microgram. Users typically need 30-50% less NA-Semax-Amidate to achieve effects comparable to standard Semax. Some users report that the amidate version has a "smoother" effect profile with less of the acute stimulant quality.

Is Semax safe for long-term use?

Semax has been used clinically in Russia for over 25 years with no reports of serious long-term adverse effects. However, this safety data comes from cycled protocols (14-28 days per cycle), not from continuous daily use over years. The cycling approach recommended in this protocol is consistent with the established safety data and provides a practical balance between cognitive benefit and responsible use. Continuous, uncycled use is not recommended due to the potential for receptor desensitization and the absence of long-term continuous-use safety data.